尿激酶静脉溶栓治疗急性脑梗死68例临床分析

摘要

目的：探讨尿激酶溶栓治疗急性脑梗死的临床疗效及安全性。方法将符合急性脑梗死诊断标准的136例患者分为2组各68例。治疗组给予尿激酶100万～150万U ，并给予除抗血小板聚集外的常规治疗；对照组给予常规治疗；2组疗程均为14 d。比较2组临床疗效、不良反应和治疗前及治疗后24 h、1周、2周的神经功能缺损评分。结果2组治疗前及治疗后24 h、1周、2周神经功能缺损评分比较差异有统计学意义（ P＜0.01）。总有效率治疗组优于对照组，差异有统计学意义（ P＜0.05）；未见明显不良反应。结论尿激酶静脉溶栓治疗急性脑梗死疗效满意，且安全性较好，能明显提高患者的生活质量。%Objective To investigate the clinical efficacy and safety of urokinase intravenous thrombolysis on treating pa‐tients with acute cerebral infarction.Methods 136 patients with acute cerebral infarction were divided into control group (n=68 ,treated with conventional medicine ) and treatment group (n=68 ,treated with conventional medicine plus urokinase ). 14d after treatment ,the clinical efficacy ,adverse reactions and neurological functions of two groups were compared.Results he neurological deficit score and total efficiency rate of treatment group were better than these of control group before treatment and 24 h ,1 week and 2 weeks after treatment ,which had significant difference. There was no significant adverse reaction be‐fore and after treatment.Conclusion Intravenous thrombolytic therapy with urokinase has better curative effect and safety on treating acute cerebral infarction and can improve the life quality of patients.